Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting
Olanzapine (Zyprexa(R)) was approved for general prescription in Sweden in November 1996, and an HPLC-based therapeutic drug monitoring (TDM) routine for serum olanzapine (OLA) and its major metabolite. N-demethylolanzapine (DMO) was established in February 1997. During 1997 to 1999, a total of 753 TDM requests for a total of 545 Swedish patients was analyi.ed. Additional patient information oil c
